Impact of an Inter-Professional Clinic on Pancreatic Cancer Outcomes: A Retrospective Cohort Study
-
Published:2024-05-02
Issue:5
Volume:31
Page:2589-2597
-
ISSN:1718-7729
-
Container-title:Current Oncology
-
language:en
-
Short-container-title:Current Oncology
Author:
Moffat Gordon Taylor1, Coyne Zachary1, Albaba Hamzeh2, Aung Kyaw Lwin3, Dodd Anna1, Espin-Garcia Osvaldo4, Moura Shari1, Gallinger Steven56ORCID, Kim John7, Fraser Adriana1, Hutchinson Shawn1, Moulton Carol-Anne6, Wei Alice8, McGilvray Ian6, Dhani Neesha1, Jang Raymond1, Elimova Elena1, Moore Malcolm1, Prince Rebecca1ORCID, Knox Jennifer1
Affiliation:
1. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 1X6, Canada 2. Department of Oncology, Jack Ady Cancer Centre, University of Alberta, Lethbridge, AB T1J 1W5, Canada 3. Livestrong Cancer Institutes and Dell Medical School, The University of Texas at Austin, Austin, TX 78712, USA 4. Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1X6, Canada 5. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital Joseph, Toronto, ON M5G 1X5, Canada 6. Toronto General Hospital, University Health Network, Toronto, ON M5G 2C4, Canada 7. Department of Radiation Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 1X6, Canada 8. Department of Surgery, Memorial Sloan Kettering Cancer Center, Weill-Cornell School of Medicine, Cornell University, New York City, NY 10065, USA
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) presents significant challenges in diagnosis, staging, and appropriate treatment. Furthermore, patients with PDAC often experience complex symptomatology and psychosocial implications that require multi-disciplinary and inter-professional supportive care management from health professionals. Despite these hurdles, the implementation of inter-professional clinic approaches showed promise in enhancing clinical outcomes. To assess the effectiveness of such an approach, we examined the impact of the Wallace McCain Centre for Pancreatic Cancer (WMCPC), an inter-professional clinic for patients with PDAC at the Princess Margaret Cancer Centre (PM). Methods: This retrospective cohort study included all patients diagnosed with PDAC who were seen at the PM before (July 2012–June 2014) and after (July 2014–June 2016) the establishment of the WMCPC. Standard therapies such as surgery, chemotherapy, and radiation therapy remained consistent across both time periods. The cohorts were compared in terms of survival rates, disease stage, referral patterns, time to treatment, symptoms, and the proportion of patients assessed and supported by nursing and allied health professionals. Results: A total of 993 patients were included in the review, comprising 482 patients pre-WMCPC and 511 patients post-WMCPC. In the multivariate analysis, adjusting for ECOG (Eastern Cooperative Oncology Group) and stage, it was found that post-WMCPC patients experienced longer median overall survival (mOS, HR 0.84, 95% CI 0.72–0.98, p = 0.023). Furthermore, the time from referral to initial consultation date decreased significantly from 13.4 to 8.8 days in the post-WMCPC cohort (p < 0.001), along with a reduction in the time from the first clinic appointment to biopsy (14 vs. 8 days, p = 0.022). Additionally, patient-reported well-being scores showed improvement in the post-WMCPC cohort (p = 0.02), and these patients were more frequently attended to by nursing and allied health professionals (p < 0.001). Conclusions: The implementation of an inter-professional clinic for patients diagnosed with PDAC led to improvements in overall survival, patient-reported well-being, time to initial assessment visit and pathological diagnosis, and symptom management. These findings advocate for the adoption of an inter-professional clinic model in the treatment of patients with PDAC.
Funder
The Princess Margaret Cancer Foundation Wallace McCain Centre for Pancreatic Cancer
Reference21 articles.
1. Committee, C.C.S.A. (2024, January 24). Available online: https://cdn.cancer.ca/-/media/files/research/cancer-statistics/2023-statistics/2023_PDF_EN.pdf. 2. Society, A.C. (2024, April 03). Cancer Facts & Figures 2024. Available online: https://www.cancer.org/cancer/types/pancreatic-cancer/detection-diagnosis-staging/survival-rates.html. 3. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N. Engl. J. Med.,2011 4. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine;Ervin;N. Engl. J. Med.,2013 5. Di Federico, A., Mosca, M., Pagani, R., Carloni, R., Frega, G., De Giglio, A., Rizzo, A., Ricci, D., Tavolari, S., and Di Marco, M. (2022). Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes. Cancers, 14.
|
|